UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549
--------------------------------------------------------------------------------

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


Date of Report (Date of earliest event reported):      October 7, 2005
                                                      --------------------------


                         PROVECTUS PHARMACEUTICALS, INC.
               (Exact Name of Registrant as Specified in Charter)


       Nevada                          0-9410                   90-0031917
--------------------------------------------------------------------------------
(State or Other Jurisdiction of      (Commission             (I.R.S. Employer
 Incorporation or Organization)      File Number)         Identification Number)

 7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee          37931
--------------------------------------------------------------------------------
       (Address of Principal Executive Offices)               (Zip Code)

Registrant's telephone number, including area code:    865/769-4011
                                                      --------------------------

--------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)





<PAGE>



Item 8.01.  Other Events.

Provectus  Pharmaceuticals,  Inc., announced that Professor John F Thompson, MD,
Director of the Sydney  Melanoma Unit,  Camperdown,  NSW,  Australia,  discussed
preliminary results from the metastatic melanoma clinical trial he is conducting
using the  Company's  lead cancer  agent,  PV-10.  Professor  Thompson  made his
remarks at The William and Ida Friday  Center for  Continuing  Education  of The
University  of North  Carolina at Chapel Hill on October 6, 2005, as part of the
course "Current Management of Melanoma:  A  Multidisciplinary  Perspective." The
Company  expects  additional  information on this clinical  study  (PV-10-MM-01,
details available at www.ClinicalTrials.gov) to be available in early 2006.





,






<PAGE>




                                   Signatures

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                      Provectus Pharmaceuticals, Inc.


Dated:   October 7, 2005              By:/s/ H. Craig Dees
                                      ------------------------------------------
                                      H. Craig Dees
                                      Chief Executive Officer
[{"type": "8-K", "sequence": "1", "filename": "pvct8k100705.txt", "description": "OTHER EVENTS - ANNOUNCEMENT", "secsgml_size_bytes": 2882}]
{"company-data": {"conformed-name": "PROVECTUS PHARMACEUTICALS INC", "cik": "0000315545", "assigned-sic": "2834", "irs-number": "900031917", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-09410", "film-number": "051129713"}, "business-address": {"street1": "7327 OAK RIDGE HWY", "street2": "SUITE B", "city": "KNOXVILLE", "state": "TN", "zip": "37931", "phone": "865-769-4011"}, "mail-address": {"street1": "7327 OAK RIDGE HWY", "street2": "SUITE B", "city": "KNOXVILLE", "state": "TN", "zip": "37931"}, "former-company": [{"former-conformed-name": "ZAMAGE DIGITAL IMAGING INC", "date-changed": "20011126"}, {"former-conformed-name": "SPM GROUP INC", "date-changed": "19920703"}]}
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549
--------------------------------------------------------------------------------

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):      October 7, 2005
                                                      --------------------------

                         PROVECTUS PHARMACEUTICALS, INC.
               (Exact Name of Registrant as Specified in Charter)

       Nevada                          0-9410                   90-0031917
--------------------------------------------------------------------------------
(State or Other Jurisdiction of      (Commission             (I.R.S. Employer
 Incorporation or Organization)      File Number)         Identification Number)

 7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee          37931
--------------------------------------------------------------------------------
       (Address of Principal Executive Offices)               (Zip Code)

Registrant's telephone number, including area code:    865/769-4011
                                                      --------------------------

--------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)
Item 8.01.  Other Events.

Provectus  Pharmaceuticals,  Inc., announced that Professor John F Thompson, MD,
Director of the Sydney  Melanoma Unit,  Camperdown,  NSW,  Australia,  discussed
preliminary results from the metastatic melanoma clinical trial he is conducting
using the  Company's  lead cancer  agent,  PV-10.  Professor  Thompson  made his
remarks at The William and Ida Friday  Center for  Continuing  Education  of The
University  of North  Carolina at Chapel Hill on October 6, 2005, as part of the
course "Current Management of Melanoma:  A  Multidisciplinary  Perspective." The
Company  expects  additional  information on this clinical  study  (PV-10-MM-01,
details available at www.ClinicalTrials.gov) to be available in early 2006.

,
Signatures

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                      Provectus Pharmaceuticals, Inc.

Dated:   October 7, 2005              By:/s/ H. Craig Dees
                                      ------------------------------------------
                                      H. Craig Dees
                                      Chief Executive Officer